Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation.

Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.

Key Stats

• Today's Range: $1.45 to $1.59
• 50-Day Range: $1.43 to $2.32
• 52-Week Range: $1.40 to $6.18
• Volume: 186,711 shs
• Average Volume: 86,701 shs
• Market Capitalization: $1.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCNI Stock Analysis - Frequently Asked Questions

How have SCNI shares performed this year?

Scinai Immunotherapeutics' stock was trading at $3.35 at the start of the year. Since then, SCNI stock has decreased by 56.7% and is now trading at $1.45.

How were Scinai Immunotherapeutics' earnings last quarter?

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($10.40) earnings per share for the quarter. The firm earned $0.21 million during the quarter.

When did Scinai Immunotherapeutics' stock split?

Shares of Scinai Immunotherapeutics reverse split on Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Scinai Immunotherapeutics?

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scinai Immunotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($9.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.80 million
• Net Margins: N/A
• Pretax Margin: 728.88%
• Return on Equity: N/A
• Return on Assets: -40.60%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 0.71
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $660 thousand
• Price / Sales: 2.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.10 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 1,000,000
• Free Float: 940,000
• Market Cap: $1.45 million
• Optionable: Not Optionable
• Beta: 1.83